ShangPharma Plans To Merge CRO/CMO Operations With Public Entity

ShangPharma will combine all of its CRO/CMO operations under the ChemPartner name and merge the entity, sometime in the future, with a public company. The merger will list the CRO/CMO operations on either the Shanghai or Shenzhen exchange. ShangPharma did not disclose whether ShangPharma intends to be the surviving company. However, ShangPharma is holding back at least two of its divisions from ChemPartner: ShangPharma Technologies, which enables new technologies, and ShangPharma Investments, which invests in new drug therapies.